Skip to main content

TAKHZYRO Takeda Pharmaceuticals Australia Pty Ltd

Product name
TAKHZYRO
Accepted date
Jun-2023
Active ingredients
lanadelumab
Proposed indication
For hereditary angioedema.
Application type
C (new medicine)
Publication date
Jun-2023
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.

Help us improve the Therapeutic Goods Administration site